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Abstract
Objectives
To evaluate the association between experience in the
management of acute pulmonary embolism, reflected
by hospital case volume, and mortality.
Design
Multinational population based cohort study
using data from the Registro Informatizado de la
Enfermedad TromboEmbólica (RIETE) registry between
1 January 2001 and 31 August 2018.
Setting
353 hospitals in 16 countries.
Participants
39 257 consecutive patients with confirmed diagnosis
of acute symptomatic pulmonary embolism.
Main outcome measure
Pulmonary embolism related mortality within 30 days
after diagnosis of the condition.
Results
Patients with acute symptomatic pulmonary
embolism admitted to high volume hospitals (>40
pulmonary embolisms per year) had a higher burden
of comorbidities. A significant inverse association was
seen between annual hospital volume and pulmonary
embolism related mortality. Admission to hospitals in
the highest quarter (that is, >40 pulmonary embolisms
per year) was associated with a 44% reduction in
the adjusted odds of pulmonary embolism related
mortality at 30 days compared with admission to
hospitals in the lowest quarter (<15 pulmonary
embolisms per year; adjusted risk 1.3% v 2.3%;
adjusted odds ratio 0.56 (95% confidence interval
0.33 to 0.95); P=0.03). Results were consistent in
all sensitivity analyses. All cause mortality at 30
days was not significantly reduced between the two
quarters (adjusted odds ratio 0.78 (0.50 to 1.22);
P=0.28). Survivors showed little change in the odds of
recurrent venous thromboembolism (odds ratio 0.76

What is already known on this topic
The number of patients treated in a hospital is a well established determinant of
outcomes after different surgical conditions
However, the contribution of experience to survival after acute pulmonary
embolism is less well understood

What this study adds
In patients with acute symptomatic pulmonary embolism, annual hospital
volume had a significantly inverse association with mortality related to
pulmonary embolism
Admission to lower volume hospitals was associated with significantly increased
odds of adjusted mortality related to pulmonary embolism at 30 days
the bmj | BMJ 2019;366:l4416 | doi: 10.1136/bmj.l4416

(0.49 to 1.19)) or major bleeding (1.07 (0.77 to 1.47))
between the low and high volume hospitals.
Conclusions
In patients with acute symptomatic pulmonary
embolism, admission to high volume hospitals
was associated with significant reductions in
adjusted pulmonary embolism related mortality at
30 days. These findings could have implications for
management strategies.

Introduction
Pulmonary embolism remains a worldwide major
health problem.1 It is among the most common causes
of vascular death after myocardial infarction and
stroke, and is the leading preventable cause of death in
patients in hospital.2 The number of patients treated in
a hospital is a well established determinant of outcomes
after different medical and surgical conditions.3-5 For
acute symptomatic pulmonary embolism, however,
the contribution of experience to survival is less well
understood.6 Treatment of pulmonary embolism is
complex and requires considerable clinical skills.
Patients with pulmonary embolism can present with
a wide variety of clinical manifestations and could
develop several complications that require timely
recognition and treatment. The optimal treatment
for patients with pulmonary embolism has markedly
evolved over the past decade.7-10 Thus, there is a
clinical priority to determine whether patients admitted
to hospitals that only occasionally treat patients
with pulmonary embolism have similar outcomes to
those admitted to hospitals that treat patients with
pulmonary embolism more frequently.
The Registro Informatizado de la Enfermedad
TromboEmbólica (RIETE) Registry is an ongoing,
multicentre, international, prospective registry of
consecutive patients with symptomatic, objectively
confirmed, acute venous thromboembolism.11-13 We
hypothesised that experience in the management
of acute pulmonary embolism, reflected by hospital
case volume, would be significantly associated with a
reduction in pulmonary embolism related mortality at
30 days, after adjustment for differences in the patient
case mix and hospital status (university based or not).
Methods
Study design
For this study, we used the data from the RIETE
registry, which prospectively collects information on
patients with confirmed acute venous thromboembo
lism (ClinicalTrials.gov NCT02832245). All patients
provided written or oral consent for participation in
1
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Patient selection
Confirmatory testing for pulmonary embolism
consisted of high probability ventilation-perfusion
scintigraphy17; positive computed tomography (CT)
pulmonary angiography for pulmonary embolism18; or
venous compression ultrasonography of the lower limb
that was positive for proximal deep vein thrombosis
(DVT) in a patient presenting with chest symptoms.19
This study included patients who were enrolled in
the RIETE registry and had a diagnosis of acute,
symptomatic pulmonary embolism from 1 January
2001 to 31 August 2018.
Hospital volume
We defined hospital volume as the mean number of
patients with pulmonary embolism per year admitted
to each hospital during its participation in the RIETE
registry. Accurate case ascertainment is essential for
clinical registries to be valid and representative. We
assessed case ascertainment in the RIETE registry
by linking 16 random Spanish registry hospitals
(four per hospital volume quarter) to the Spanish
National Patient Registry during 2017 (see methods
section in the supplementary appendix). Firstly, we
used volume as a continuous variable to examine
the association between hospital volume and the
outcomes. We then categorised the volume of patients
into volume quarters, with the lowest volume quarter
(<15 patients/year) as the reference category. We chose
volume quarters of patients to ensure a minimum
number of hospitals in each volume category and
to protect hospital identity. We also estimated the
volume threshold above which an increase in volume
was not associated with a reduction in the odds of an
adverse outcome, by determining the change in the
adjusted odds ratio associated with an increase in the
pulmonary embolism volume by 10 cases. We defined
the volume threshold as the annual hospital volume
for which the relative change in the adjusted odds of
the outcome associated with an increase of 10 patients
with acute pulmonary embolism would be less than
0.01 (that is, an odds ratio more than 0.99). To
characterise the variation of the estimated threshold,
we used bootstrapping techniques and replicated
2

this analysis in 500 bootstrap samples to obtain 95%
confidence intervals for the volume threshold.

Study outcomes
The primary outcome was mortality related to
pulmonary embolism at 30 days after diagnosis
of the condition. The secondary outcome was all
cause mortality at 30 days. We also examined the
rates of death (all cause and related to pulmonary
embolism) within seven days following the diagnosis
of pulmonary embolism. The RIETE investigators
used medical record review to assess vital status.
For patients who died, further medical record review
(and proxy interviews when necessary) assisted with
determining the date and cause of death. For deaths
confirmed by autopsy or those following a clinically
severe pulmonary embolism (either initially or shortly
after an objectively confirmed recurrent event), in the
absence of any alternative diagnosis, the investigators
were instructed to judge death as due to fatal
pulmonary embolism. We also examined the rates of
non-fatal recurrence of venous thromboembolism, and
non-fatal bleeding events within 30 days following
the diagnosis of pulmonary embolism (see methods
section in the supplementary appendix).
Statistical analysis
Because the proportions of missing data (for
covariates) were below 5%, we assumed that the
missing data were unlikely to drive the results of our
study and as such, we analysed the observed data
(complete case analysis). We performed χ2 tests for
categorical variables and analyses of variance for
continuous variables to compare the demographic and
clinical characteristics of patients across the quarters
of hospital volume. We reported the use of reperfusion
treatments for pulmonary embolism, and appropriate
treatment in patients admitted to each quarter of
hospitals.
To assess the relation between hospital volume and
the outcomes of interest, we constructed hierarchical
multivariable logistic regression models for the overall
cohort. To address potential confounding due to case
mix variation, we controlled for the severity of illness
and additional variables related to the outcome of
patients with acute pulmonary embolism. The following
models were generated sequentially to determine the
successive influence of potential confounders on the
relation between hospital volume and mortality:
•
•
•

•

Unadjusted
Adjusted only for age and sex
Adjusted for age, sex, and the following covariates:
coexisting conditions (cancer, immobilisation,
chronic lung disease, chronic heart disease),
severity of pulmonary embolism (heart rate,
systolic blood pressure), and laboratory results
(creatinine levels, haemoglobin levels) at hospital
admission
Adjusted for age, sex, cancer, immobilisation,
chronic lung disease, chronic heart disease,
doi: 10.1136/bmj.l4416 | BMJ 2019;366:l4416 | the bmj
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the registry in accordance with local ethics committee
requirements. Previous publications have described
the design and conduct of the RIETE registry.14 15
Briefly, at each participating RIETE site, investigators
enrolled consecutive patients with acute venous
thromboembolism. To ensure the reliability of coding
and data entry, trained monitors periodically visited
each participating hospital and compared the
information in a random sample of hospital charts
with the information entered into the RIETE database.
RIETE also uses electronic data monitoring to prevent
inconsistent or implausible values. In fact, previous
studies have shown that data from RIETE closely
represents that of multicentre administrative data,
further supporting the representativeness and the
validity of the data elements.16

RESEARCH

All these models were built at the patient level,
with hospital volume as a predictor variable with four
categories. In all models, we accounted for clustering
of patients within hospitals and hospitals clustered
within countries. Interaction terms for year of
diagnosis were included initially in the hospital level
model, with a prespecified plan to remove this variable
if no interaction was found.
We performed several sensitivity analyses. These
analyses comprised the exclusion of outlier hospitals
(those with too few or too many patients), exclusion
of patients younger than 50 years old, exclusion of
haemodynamically unstable patients, and exclusion
of patients who received reperfusion treatments.
Additional analyses included a falsification hypothesis
analysis in which the cohort was evaluated for death
related to cancer, chronic heart disease, and infection
at 90 days. We also did alternative event rate estimation
using inverse probability weighted regression adjust
ment (supplementary appendix). All analyses were
conducted with Stata version 13.1 (Stata, College
Station, TX, USA). All hypothesis tests were two sided,
with a significance level of 0.05.

Patient and public involvement
Patients were not involved in the design of this study, the
choice of the outcome measures, or analysis of the data
or dissemination. The study results will be available to
patients, health professionals, and experts in the specialty
through various channels: written communication,
events and conferences, networks, social media, and
patient-practitioner websites (including https://trombo.
info/about-us/?lang=en, where some RIETE investigators
share data with practitioners and patients).
Results
The study included 39 257 patients with pulmonary
embolism from 353 hospitals in 16 countries (fig
1). The linked data showed that the RIETE registry
captured about 84% of the patients (n=602/718) with
a final diagnosis of pulmonary embolism from each
hospital, with little variation according to hospital
volume (table S1, supplemental appendix). Annual
hospital volume ranged from one to 112 admitted
patients with pulmonary embolism per year (median 7;
interquartile range 4-16). The final cohort was divided
into four quarters of hospital volume, roughly equally
sized, with about 10 000 patients in each quarter.
Patients admitted to higher volume hospitals and
those admitted to lower volume hospitals differed in
pre-existing medical conditions, and relevant clinical,
the bmj | BMJ 2019;366:l4416 | doi: 10.1136/bmj.l4416

physiological, and laboratory parameters. Patients
admitted to higher volume hospitals were older, had
more comorbid diseases (cancer, chronic lung disease,
congestive heart failure, and recent bleeding), and
more signs of clinical severity (high risk according to
sPESI, tachycardia, hypoxaemia, and hypotension)
than those admitted to lower volume hospitals
(table 1). Regarding in-hospital reperfusion treat
ments, patients at low volume centres were more likely
to receive reperfusion treatments (mostly systemic
thrombolysis; 3.9% v 3.0%, P<0.001) and less likely
to receive an inferior vena cava filter (2.7% v 3.3%,
P=0.006). Compared with those admitted to high
volume hospitals, patients at low volume centres
were more likely to receive management that did not
adhere to clinical practice guidelines (17.6% (n=1512)
v 14.2% (n=1821), P<0.001; table S2, supplemental
appendix).
The study had complete information on the
primary outcome for all patients at the end of the
30 day follow-up. At 30 days, the entire cohort had
an all cause mortality rate of 5.4% (2139 of 39 257
patients), and pulmonary embolism related mortality
rate of 1.7% (668 of 39 257 patients; table 2). When
examined as a completely continuous variable
(between 1 and 112), hospital volume was associated
with a significant reduction in the adjusted odds of
pulmonary embolism related mortality rates at 30 days
(P=0.04 for linear trend; fig 2). We saw no significant
interaction between the volume-mortality relation and
the year of pulmonary embolism diagnosis (P=0.99
for interaction). There was not a specific volume
threshold above which an increase in volume was not
associated with a reduction in the odds of an adverse
outcome. Compared with patients in the lowest quarter
of hospital volume (quarter 1), patients in quarters
2, 3, and 4 had a reduction in the adjusted odds of
pulmonary embolism related death at 30 days of
34% (P=0.06), 39% (P=0.05), and 44% (P=0.03),
respectively (table 3 and table S3). The adjusted risk
of pulmonary embolism related death at 30 days
was 2.3% for patients in the lowest volume quarter
and 1.3% for patients in the highest volume quarter
(table 3).
Adjusted all cause mortality at 30 days was 5.2%
for patients admitted to hospitals in the highest
quarter and 6.4% for patients admitted to hospitals
in the lowest quarter (table 3; odds ratio 0.78, 95%
confidence interval 0.50 to 1.22; P=0.28). Similar
findings were observed for all cause mortality and
pulmonary embolism related mortality at seven
days. At seven days, the adjusted risk of pulmonary
embolism related death was 1.7% for patients in
the lowest quarter of hospital volume and 1.0% for
patients in the highest quarter, and the adjusted risk
of all cause mortality was 2.7% for patients in the
lowest quarter and 2.1% for patients in the highest
quarter (table 3). Among survivors, we saw no clear
association between hospital volume and non-fatal
recurrence or major bleeding. Compared with the
lowest quarter of hospital volume, higher volume was
3
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•

heart rate, systolic blood pressure, simplified
pulmonary embolism severity index (sPESI),20
creatinine levels, and haemoglobin levels
(predefined main analysis)
Adjusted for age, sex, cancer, immobilisation,
chronic lung disease, chronic heart disease, heart
rate, systolic blood pressure, sPESI, creatinine
levels, haemoglobin levels, and hospital status
(university based or not).

RESEARCH

37 770
Excluded without symptomatic pulmonary embolism
36 127 Had deep vein thrombosis without symptomatic
pulmonary embolism
1643 Had asymptomatic pulmonary embolism
39 257
Patients with acute symptomatic pulmonary embolism at 353 hospitals

Fig 1 | STROBE study cohort flow diagram

not associated with a significant reduction in non-fatal
recurrent venous thromboembolism in quarters 2, 3,
and 4 (odds ratio 0.82 (95% confidence interval 0.54
to 1.23), 0.74 (0.48 to 1.14), and 0.76 (0.49 to 1.19),
respectively). We saw no significant difference in the
incidence of non-fatal major bleeding events among
hospital volume quarters (table 3).
To explore the sensitivity of our findings, we repeated
the analysis with varying assumptions about the
patient population and hospitals (table 4). Our results
were not affected by the exclusion of younger patients
(that is, age <50), haemodynamically unstable patients

(that is, systolic blood pressure <90 mm Hg), patients
who received reperfusion treatments, or exclusion of
outlier hospitals.
We performed a falsification hypothesis analysis
using the outcome of mortality related to cancer,
chronic heart disease, and infection at 90 days.
Compared with patients in the lowest quarter of
hospital volume (quarter 1), patients in quarters 2,
3, and 4 did not have a significant reduction in the
adjusted odds of death at 90 days related to cancer
(odds ratio 1.52 (95% confidence interval 1.06 to
2.19), 1.57 (1.05 to 2.33), and 1.52 (1.00 to 2.31),
respectively), chronic heart disease (1.25 (0.65 to
2.40), 1.05 (0.52 to 2.09), and 0.86 (0.42 to 1.73),
respectively), and infection (1.06 (0.61 to 1.82), 0.86
(0.48 to 1.55), and 1.34 (0.74 to 2.44), respectively;
table S4, supplementary appendix). The propensity
score analysis confirmed reduced mortality related
to pulmonary embolism for patients admitted to high
volume hospitals, thereby supporting the primary
results (table S5, supplementary appendix).

Discussion
Principal findings
These data show an association between an increase
in hospital volume of patients with pulmonary

Table 1 | Baseline characteristics in patients with acute pulmonary embolism by hospital volume quarter (Q)
Hospital volume

Hospital characteristics
No of hospitals
No of beds (mean (SD))
Teaching hospitals
Patient characteristics
Patients
Age (mean (SD))
Age >80
Male sex
Weight (kg; mean (SD))
History of VTE
Cancer*
Recent surgery†
Immobilisation for ≥4 days‡
Chronic lung disease
Chronic heart disease
Recent major bleeding
Pulse (beats; mean (SD))
Pulse ≥110 beats/min
Systolic blood pressure (mm Hg; mean (SD))
Systolic blood pressure <100 mm Hg
Arterial oxyhaemoglobin saturation <90%
sPESI20
Low risk
High risk
Abnormal creatinine levels (>176.8 µmol/L)
Haemoglobin (g/L; mean (SD))
Inappropriate management§
Reperfusion treatment
IVC filter insertion

Q1 (<15 patients/year)

Q2 (15-25 patients/year)

Q3 (>25-40 patients/year)

Q4 (>40 patients/year)

253
520 (428)
88 (35)

52
605 (361)
16 (31)

28
831 (516)
18 (64)

20
861 (342)
13 (65)

8596
65.6 (17.6)
2024 (23.5)
4050 (47.1)
76.5 (16.0)
5069 (61.9)
1751 (20.4)
1010 (11.7)
2038 (23.7)
1162 (13.5)
705 (8.2)
209 (2.4)
93.0 (19.7)
1744 (21.4)
128.3 (23.7)
651 (7.6)
1971 (38.5)

8130
67.2 (16.9)
2160 (26.6)
3756 (46.2)
75.9 (16.3)
5339 (67.8)
1861 (22.9)
898 (11.0)
1894 (23.3)
1142 (14.0)
718 (8.8)
196 (2.4)
91.9 (20.0)
1492 (19.5)
130.6 (23.1)
537 (6.6)
1639 (33.9)

9750
68.0 (16.4)
2670 (27.4)
4593 (47.1)
76.8 (16.2)
6488 (68.4)
1875 (19.2)
1186 (12.2)
2040 (20.9)
1340 (13.7)
808 (8.3)
188 (1.9)
91.8 (20.0)
1903 (19.7)
130.3 (24.3)
724 (7.4)
1947 (32.3)

12 781
67.7 (16.7)
3440 (26.9)
5968 (46.7)
75.4 (16.4)
8931 (71.1)
3287 (25.7)
1504 (11.8)
2852 (22.3)
1918 (15.0)
1293 (10.1)
349 (2.7)
93.5 (20.2)
2819 (22.3)
128.6 (24.5)
1217 (9.5)
3015 (38.4)

2755 (32.0)
5841 (68.0)
1505 (18.2)
130 (21)
1512 (17.6)
334 (3.9)
230 (2.7)

2502 (30.8)
5628 (69.2)
1542 (20.1)
130 (21)
1251 (15.4)
206 (2.5)
224 (2.8)

3193 (32.7)
6557 (67.3)
1971 (20.6)
131 (20)
1453 (14.9)
326 (3.3)
255 (2.6)

3586 (28.1)
9195 (71.9)
2381 (18.9)
130 (20)
1821 (14.2)
383 (3.0)
423 (3.3)

Data are number (%) of patients unless stated otherwise. SD=standard deviation; VTE=venous thromboembolism; sPESI=simplified pulmonary embolism severity index; IVC=inferior vena cava.
*Active or under treatment in previous year.
†In previous month.
‡Immobilised patients defined as non-surgical patients who had been immobilised (that is, total bed rest with bathroom privileges) for at least four days in the month before diagnosis of
pulmonary embolism.
§Definition of inappropriate management provided in the supplemental appendix.
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Table 2 | Observed rates of mortality and non-fatal outcomes by hospital volume quarter (Q)
Hospital volume
Q1 (<15 patients/year) Q2 (15-25 patients/year)

Q3 (>25-40 patients/year) Q4 (>40 patients/year)

201/8596 (2.3)
525/8596 (6.1)
153/8596 (1.8)
236/8596 (2.7)

125/8130 (1.5)
433/8130 (5.3)
91/8130 (1.1)
169/8130 (2.1)

148/9750 (1.5)
459/9750 (4.7)
110/9750 (1.1)
191/9750 (2.0)

194/12 781 (1.5)
722/12 781 (5.6)
154/12 781 (1.2)
291/12 781 (2.3)

94/8596 (1.1)
299/8596 (3.5)

69/8130 (0.8)
270/8130 (3.3)

75/9750 (0.8)
352/9750 (3.6)

125/12 781 (1.0)
496/12 781 (3.9)

PE=pulmonary embolism; VTE=venous thromboembolism.

embolism and a lower risk adjusted mortality related
to pulmonary embolism at 30 days. We observed a
consistent dose-response relation between hospital
volume and pulmonary embolism related mortality.
The results were consistent with use of various
adjustment techniques, across major subgroups of
the patient populations and modelling assumptions,
and were less likely to be driven by unmeasured
confounding, represented by the lack of association
between hospital volume of patients with pulmonary
embolism and the falsification endpoints.

Adjusted odds of pulmonary
embolism related mortality (%)

Comparison with other studies
Few studies have investigated whether hospitals that
care for large numbers of patients with pulmonary
embolism have a lower short term mortality than those
caring for low numbers of such patients.6 In a study
of 10 354 patients admitted to hospital for pulmonary
embolism based on administrative data from 186
Pennsylvania hospitals, Aujesky and colleagues found
that the hospitals with higher annual volumes (≥42
patients/year) of patients with pulmonary embolism
had significantly lower in-hospital and all cause
mortality at 30 days than the hospitals with very low
volumes (<10 patients/year). Our study’s large sample
size, availability of good quality clinical data that
allowed for adjustment for potential confounders,
availability of cause specific mortality, availability of
falsification endpoints, and robustness of the findings
across multiple sensitivity analyses provide evidence
supporting the concept that patients with acute
symptomatic pulmonary embolism admitted to high
4
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Fig 2 | Relation between hospital volume and pulmonary embolism related mortality.
Data are adjusted odds ratios (95% confidence intervals)
the bmj | BMJ 2019;366:l4416 | doi: 10.1136/bmj.l4416

volume hospitals are more likely to survive than those
admitted to low volume hospitals.

Meaning of the study
The relation between hospital volume of pulmonary
embolism and outcome among patients with
acute pulmonary embolism could have several
explanations. Medical teams at low volume hospitals
could be less experienced in providing care to
patients with pulmonary embolism (including lack
of timely recognition of clinical deterioration, lack
of multidisciplinary efforts to stabilise the patients
such as the use of pulmonary embolism response
teams (PERTs), or lack of adherence to guidelines and
available evidence for routine or advanced treatments),
which could lead to worse outcomes in patients at such
institutions. In fact, our study showed that clinicians
at low volume hospitals adhered to evidence based
guidelines less frequently, which has been shown to
correlate with patient outcomes.21
Our findings have implications on how best to manage
patients with acute symptomatic pulmonary embolism
in the future. Educational strategies could be developed
towards improving the knowledge and clinical expertise
of physicians from low volume hospitals. Improved
knowledge is particularly important because we observed
evidence of both overtreatment and undertreatment
with reperfusion treatments for pulmonary embolism
in low volume hospitals (table S2). Thus, initiatives that
could help improve the practitioners’ knowledge and
adherence to guidelines recommendations at low volume
hospitals, timely transfer of patients with pulmonary
embolism (especially severe cases) to high volume
hospitals, and dissemination of PERT teams across the
hospitals (such as multidisciplinary teams caring for
patients with ST elevation myocardial infarction) could
be considered. Currently, little evidence exists on the
benefits of PERT teams for improving patient outcomes,
quality of life, and cost.22-25 Findings from our study
would reinforce the interest in this area, which deserves
focused investigations.
Strengths and limitations of study
Our study had several potential limitations. Firstly,
despite our best efforts, the possibility of residual
confounding still remains. Nevertheless, we did adjust
for age, sex, comorbidities, severity of pulmonary
embolism, and laboratory results, and still found
5
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Overall/total No (%)
of patients
Mortality
30 day PE related mortality
30 day all cause mortality
7 day PE related mortality
7 day all cause mortality
Non-fatal complications
30 day VTE recurrence
30 day major bleeding
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Table 3 | Adjusted rates of mortality and non-fatal outcomes by hospital volume quarter (Q)*
Hospital volume
Q1 (<15 patients/year)

Q2 (15-25 patients/year)

Q3 (>25-40 patients/year)

Q4 (>40 patients/year)

1.0
1.0
1.0
1.0
1.0
1.0

0.66 (0.43 to 1.01)
0.68 (0.48 to 0.97)
0.65 (0.41 to 1.02)
0.72 (0.48 to 1.07)
0.82 (0.54 to 1.23)
0.92 (0.70 to 1.20)

0.61 (0.38 to 0.99)
0.73 (0.19 to 1.10)
0.68 (0.42 to 1.11)
0.72 (0.46 to 1.12)
0.74 (0.48 to 1.14)
0.90 (0.66 to 1.22)

0.56 (0.33 to 0.95)
0.78 (0.50 to 1.22)
0.60 (0.35 to 1.03)
0.76 (0.47 to 1.24)
0.76 (0.49 to 1.19)
1.07 (0.77 to 1.47)

2.3 (1.8 to 2.8)
6.4 (5.4 to 7.3)
1.7 (1.3 to 2.1)
2.7 (2.1 to 3.2)
1.1 (0.8 to 1.4)
3.6 (3.1 to 4.2)

1.5 (1.0 to 2.1)
4.7 (3.5 to 5.8)
1.1 (0.7 to 1.5)
2.0 (1.4 to 2.6)
0.9 (0.5 to 1.1)
3.2 (2.5 to 3.9)

1.4 (0.9 to 2.0)
4.9 (3.5 to 6.4)
1.2 (0.7 to 1.6)
2.0 (1.3 to 2.7)
0.8 (0.5 to 1.1)
3.8 (2.9 to 4.7)

1.3 (0.7 to 1.9)
5.2 (3.4 to 7.0)
1.0 (0.6 to 1.5)
2.1 (1.3 to 2.9)
0.8 (0.5 to 1.2)
3.9 (2.8 to 4.9)

PE=pulmonary embolism; VTE=venous thromboembolism.
*Adjusted for age, sex, cancer, immobilisation, chronic lung disease, chronic heart disease, heart rate, systolic blood pressure, simplified pulmonary embolism severity index, creatinine levels,
and haemoglobin levels at hospital admission. Confidence intervals and P values take into account clustering according to centre.
†Event rates were compared across quarters of hospital volume according to adjusted odds ratios (with 95% confidence intervals); the lowest quarter served as the reference group.
‡Adjusted values were determined with the main model evaluating hospital volume categorised into quarters.

a consistent relation between hospital volume and
outcome. The severity of pulmonary embolism might
have accounted for some of the differences between the
groups’ outcomes. However, because patients admitted
to higher volume hospitals had more signs of clinical
severity, the study findings suggest that the design
might have caused a bias against hospital volume.
Furthermore, the results of sensitivity analyses and
falsification hypothesis analyses made it less likely
that our results were driven by unmeasured residual
confounding, and provided evidence of the robustness
of the findings. In addition, the single data point of
initial blood pressure and heart rate used to define
severity could have affected our analysis. However,
based on current guidelines and the published
literature, prognostication of pulmonary embolism
is based on the findings at the time of pulmonary
embolism diagnosis.
Secondly, similar to most studies looking into
an association between volume and outcomes,
our analysis cannot determine the direction of the
association (that is, causality).26 Although high
volume hospitals had better adherence to guideline
recommendations in our study, their good quality
of care might have been a driver in attracting more
patients with pulmonary embolism, thereby increasing
their volume. Additional qualitative and mixed

methods research is needed to further understand the
reasons for better outcomes in high volume centres,
and the major areas for improvement in low volume
centres. Although this study was performed over a long
period of time, we did not find significant interaction
between the volume-mortality relation and year of
pulmonary embolism diagnosis. Finally, because our
study cohort probably included hospitals that were
enthusiastic about evidence based management
of pulmonary embolism, reductions in mortality
associated with increases in the annual volume of
patients treated could be more pronounced compared
with other hospitals where vested teams of motivated
physicians for pulmonary embolism management
do not exist. However, the RIETE registry is the only
large scale, multinational, observational study of the
spectrum of patients diagnosed with a pulmonary
embolism, with continuous recruitment of patients for
more than 10 years, and offers a unique opportunity to
look at a large number of patients in various treatment
settings, countries, and continents over a long period
of time.

Conclusions and policy implications
We observed an inverse association between annual
hospital volume of pulmonary embolism and outcomes
among patients with acute symptomatic pulmonary

Table 4 | Sensitivity analysis for rates of pulmonary embolism related mortality*
Model
Main model
Excluding outlier hospitals†
Excluding hospitals with annual volume <5 patients/year
Excluding hospitals with annual volume >80 patients/year
Excluding younger patients (age <50)
Excluding unstable patients (systolic blood pressure <90 mm Hg)
Excluding patients who received reperfusion treatments‡

No of patients
39 257
33 142
36 585
34 295
30 770
35 916
35 962

No of hospitals
353
231
256
344
345
348
345

Odds ratio (95% CI)
0.56 (0.33 to 0.95)
0.53 (0.28 to 0.97)
0.57 (0.33 to 0.98)
0.50 (0.28 to 0.91)
0.51 (0.30 to 0.87)
0.59 (0.35 to 1.03)
0.53 (0.30 to 0.91)
*Odds ratios and 95% confidence intervals compare the highest quarter of hospital volume (>40 patients/year) with the lowest quarter (<15 patients/

year). Models adjusted for age, sex, cancer, immobilisation, chronic lung disease, chronic heart disease, heart rate, systolic blood pressure, simplified
pulmonary embolism severity index, creatinine levels, and haemoglobin levels at hospital admission. Confidence intervals take into account clustering
according to centre.
†Outlier hospitals in terms of volume excluded (annual volumes <5 or >80 patients/year).
‡Including systemic thrombolysis, catheter directed treatment, or surgical embolectomy.
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Variable
Odds ratio (95% CI)†
30 day PE related mortality
30 day all cause mortality
7 day PE related mortality
7 day all cause mortality
30 day non-fatal VTE recurrence
30 day non-fatal major bleeding
Adjusted risk (%; 95% CI)‡
30 day PE related mortality
30 day all cause mortality
7 day PE related mortality
7 day all cause mortality
30 day non-fatal VTE recurrence
30 day non-fatal major bleeding
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